Generic Edurant Ped Availability
Last updated on May 9, 2024.
See also: Generic Edurant
Edurant Ped is a brand name of rilpivirine, approved by the FDA in the following formulation(s):
EDURANT PED (rilpivirine hydrochloride - tablet, for suspension;oral)
-
Manufacturer: JANSSEN PRODS
Approval date: March 15, 2024
Strength(s): EQ 2.5MG BASE [RLD]
Has a generic version of Edurant Ped been approved?
No. There is currently no therapeutically equivalent version of Edurant Ped available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Edurant Ped. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Dispersible compositions
Patent 11,065,198
Issued: July 20, 2021
Inventor(s): Patankar Harshad & Goyvaerts Nicolaas Martha Felix & Ranga Rajan Gopal Rajan
Assignee(s): Janssen Sciences Ireland Unlimited CompanyThe present invention is concerned with dispersible compositions comprising rilpivirine or a pharmaceutically acceptable acid addition salt thereof as an active ingredient. Such compositions are useful in the treatment of HIV infection and their dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.
Patent expiration dates:
- October 23, 2037✓
- October 23, 2037
-
Patent 7,125,879
Patent expiration dates:
- April 21, 2025✓✓✓
- April 21, 2025
More about Edurant Ped (rilpivirine)
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- Drug class: NNRTIs
- Breastfeeding
Patient resources
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.